Cargando…
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different type...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462078/ https://www.ncbi.nlm.nih.gov/pubmed/34621472 http://dx.doi.org/10.4240/wjgs.v13.i9.953 |
_version_ | 1784572123395653632 |
---|---|
author | Zhao, Yang Liu, Yu Zhou, Lin Du, Guo-Sheng He, Qiang |
author_facet | Zhao, Yang Liu, Yu Zhou, Lin Du, Guo-Sheng He, Qiang |
author_sort | Zhao, Yang |
collection | PubMed |
description | The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different types of immunosuppressive agents after LT is closely associated with an increased risk for HCC recurrence. The most commonly used conventional immunosuppressive drugs include the calcineurin inhibitors tacrolimus (FK506) and mammalian target of rapamycin inhibitor rapamycin (RAPA). Compared with tacrolimus, RAPA may carry an advantage in survival benefit because of its anti-tumor effects. However, no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear. In this review, we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice. |
format | Online Article Text |
id | pubmed-8462078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-84620782021-10-06 Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma Zhao, Yang Liu, Yu Zhou, Lin Du, Guo-Sheng He, Qiang World J Gastrointest Surg Minireviews The proportion of liver transplantation (LT) for hepatocellular carcinoma (HCC) has kept on increasing over the past years and account for 20%-40% of all LT. Post-transplant HCC recurrence is considered the most important factor affecting the long-term survival of patients. The use of different types of immunosuppressive agents after LT is closely associated with an increased risk for HCC recurrence. The most commonly used conventional immunosuppressive drugs include the calcineurin inhibitors tacrolimus (FK506) and mammalian target of rapamycin inhibitor rapamycin (RAPA). Compared with tacrolimus, RAPA may carry an advantage in survival benefit because of its anti-tumor effects. However, no sufficient evidence to date has proven that RAPA could increase long-term recurrence-free survival and its anti-tumor mechanism of combined therapy remains incompletely clear. In this review, we will focus on recent advances in clinical application experience and basic research results of RAPA in patients undergoing LT for HCC to further guide the clinical practice. Baishideng Publishing Group Inc 2021-09-27 2021-09-27 /pmc/articles/PMC8462078/ /pubmed/34621472 http://dx.doi.org/10.4240/wjgs.v13.i9.953 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Zhao, Yang Liu, Yu Zhou, Lin Du, Guo-Sheng He, Qiang Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title_full | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title_fullStr | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title_full_unstemmed | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title_short | Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
title_sort | trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462078/ https://www.ncbi.nlm.nih.gov/pubmed/34621472 http://dx.doi.org/10.4240/wjgs.v13.i9.953 |
work_keys_str_mv | AT zhaoyang trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma AT liuyu trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma AT zhoulin trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma AT duguosheng trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma AT heqiang trendsofrapamycininsurvivalbenefitsoflivertransplantationforhepatocellularcarcinoma |